TLR9 binds HCQ

Stable Identifier
R-HSA-9679045
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Toll-like receptor 9 (TLR9) is a key component of innate and adaptive immunity. It controls the host immune response against pathogens by stimulating dendritic cells and macrophages to secrete interferon alpha and other proinflammatory and regulatory cytokines (Lenert 2010). Hydroxychloroquine (HCQ) binds and antagonises TLR9 (Lamphier et al. 2014), and thus inhibits interferon alpha production. HCQ is used clinically to treat systemic lupus erythromatosis and other autoimmune disorders (Costedoat Chalumeau et al. 2014).

HCQ’s immunomodulatory properties may be useful for treatment of patients with COVID-19 (Sinha & Balayla 2020, Colson et al. 2020, Gautret et al. 2020).

Literature References
PubMed ID Title Journal Year
24342772 Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo

Lamphier, M, Zheng, W, Latz, E, Spyvee, M, Hansen, H, Rose, J, Genest, M, Yang, H, Shaffer, C, Zhao, Y, Shen, Y, Liu, C, Liu, D, Mempel, TR, Rowbottom, C, Chow, J, Twine, NC, Yu, M, Gusovsky, F, Ishizaka, ST

Mol. Pharmacol. 2014
24855048 Hydroxychloroquine: a multifaceted treatment in lupus

Costedoat-Chalumeau, N, Dunogué, B, Morel, N, Le Guern, V, Guettrot-Imbert, G

Presse Med 2014
Participants
Participant Of
Authored
Reviewed
Created
Cite Us!